Analgesic nephropathy historical perspective
Jump to navigation
Jump to search
|
Analgesic nephropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Analgesic nephropathy historical perspective On the Web |
|
American Roentgen Ray Society Images of Analgesic nephropathy historical perspective |
|
Risk calculators and risk factors for Analgesic nephropathy historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
In 1953, the association between analgesic drugs and chronic renal disease was first reported in German. In 1977, Australia was first to legally ban phenacetin. In 1983, phenacetin was withdrawn from the US markets.
Historical Perspective
- In 1887, phenacetin was introduced as an analgesic which later became know that is metabolized to acetaminophen.[1]
- In 1893, acetaminophen was introduced as an analgesic.[1]
- In 1953, the association between analgesic drugs and chronic renal disease was first reported in German.[2]
- In 1977, phenacetin became legally banned in Australia.[3]
- In 1978, phenacetin was withdrawn from the Canadian markets.[4]
- In 1980, phenacetin was withdrawn from the markets in the United Kingdom.[4]
- In 1983, phenacetin was withdrawn from the US markets.[5]
References
- ↑ 1.0 1.1 Foye, William (2008). Foye's principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817-6879-5. OCLC 145942325.
- ↑ Spühler O, Zollinger HU (1953). "Die chronisch-interstitielle Nephritis". Z Klin Med (in German). 151 (1): 1–50. PMID 13137299.
- ↑ Michielsen P, de Schepper P (2001). "Trends of analgesic nephropathy in two high-endemic regions with different legislation". J. Am. Soc. Nephrol. 12 (3): 550–6. PMID 11181803. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 "Some pharmaceutical drugs". IARC Monogr Eval Carcinog Risk Chem Hum. 24: 1–337. 1980. PMID 6937434.
- ↑ "List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule". Fed Regist. 64 (44): 10944–7. 1999. PMID 10557618.